Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 03/07

20070073039 - Peptides that inhibit viral infections: The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070073040 - Anti-obesity polypeptides: The present invention relates to anti-obesity polypeptides for restraining the generation of adipose tissue in vivo. The anti-obesity polypeptides can be used as obesity preventive vaccines or treating agents and in curing diabetes.... Agent: Jones Day

20070073041 - Human tumor necrosis factor receptor polypeptides: Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070073042 - Novel mhc ii associated peptides: The present invention provides novel naturally-processed antigenic peptides which are candidate tumor antigens in melanoma and other tumors. These antigenic peptides are presented by human MHC class II HLA-DR molecules. They originate from the translation factor eIF-4A, the IFN-gamma-inducible protein p78, the cytoskeletal protein vimentin and the iron-binding surface protein... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070073043 - Process for producing humanized chimera antibody: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.... Agent: Nixon & Vanderhye, PC

20070073044 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070066798 - Diagnostic and therapeutic use of antibodies against the urokinase receptor: The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070066799 - Compatible-multiphase organic solvent system: A solvent system which comprises two or more single organic solvents or two or more mixed organic solvents, characterized in that the state of the solvent system can be reversibly changed, with changing temperature conditions, from one state which is a homogeneously compatibilized mixed solvent system in which the two... Agent: Hahn & Voight PLLC

20070066800 - Apo2l(trail) receptor binding peptides and uses thereof: Peptides are provided that bind Apo-2L receptor molecules. These peptides can be used for example in methods where a modulation of the biological activities of Apo-2L and/or Apo-2L receptor molecules such as DR5 is desired.... Agent: Genentech, Inc.

20070066802 - Chimeric receptors with disrupted dileucine motifs: A simple disruption of a dileucine motif in chimeric cell membrane receptors is taught. The disruption increases the capacity of the modified receptor to accumulate on the cell membrane relative to the unmodified receptor. The invention is particularly well suited for chimeric receptors comprising a portion of the CD28 protein... Agent: St. Jude Children's Research Hospital Office Of Technology Licensing

20070066805 - Human tumor necrosis factor receptor: Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070066801 - Identification of reagents for the diagnosis and study of francisella: Novel reagents capable of identifying, or aiding in the identification of, Francisella strains, such as, but not limited to, those identified in playing a role in human diseases or those identified as capable of being used as a biological weapon, are disclosed. In addition, methods for the identification and isolation... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20070066803 - Method to control tumor progression and invasiveness: Described is a method of modulating E-cadherin mediated cell adhesion. More specifically, described is the use of hECRep1a and homologues thereof to modulate and/or control tumor cell invasiveness.... Agent: Trask Britt

20070066804 - Tumor antigen: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises... Agent: Sughrue Mion, PLLC

20070066807 - Cytokine zalpha11 ligand fusion proteins: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070066808 - Cytokine zalpha11 ligand fusion proteins: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070066806 - Separation methods: Separation methods, for example, to isolate a recombinant protein, are disclosed. In some implementations, a method includes forming a solid containing a first cation and a first anion in a medium containing a protein, and separating the solid from the protein.... Agent: Fish & Richardson PC

20070066809 - Monoclonal antibodies to gastrin hormone: The present invention provides monoclonal antibodies (MAbs) selective for the N-termini and C-termini of the gastrin hormone forms, gastrin-17 (G17), glycine-extended gastrin-17 (G17-Gly), gastrin-34 (G34) and glycine-extended gastrin-34 (G34-Gly); and the hybridomas that produce these MAbs. Also provided are panels of MAbs useful for the detection and quantitation of gastrin-17... Agent: Fish & Richardson, PC

20070066811 - Adipocyte complement related protein zacrp3x2: Novel zacrp3x2 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp3x2 protein or fragments thereof.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070066810 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070066812 - Fibroblast growth factor homologous factor-2 and methods of use: A novel growth factor, fibroblast growth factor homologous factor-2 (FHF-2) polypeptide, the polynucleotide sequence encoding FHF-2 and the deduced amino acid sequence are disclosed. Also disclosed are diagnostic and therapeutic methods of using the FHF-2 polypeptide and polynucleotide sequences and antibodies which specifically bind to FHF-2.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper Rudnick Gray Gary US LLP

20070066813 - Modified transferrin fusion proteins: Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.... Agent: Morgan Lewis & Bockius LLP

20070060740 - Protein crystal: The present invention is in the fields of biotechnology, protein purification and crystallization, x-ray diffraction analysis, three-dimensional computer molecular modelling and rational drug design. The invention is directed to the Liver X receptor and ligands for this receptor, and in particular to crystalline Liver X receptor beta (LXRβ) and to... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20070060741 - Method of weak partitioning chromatography: This invention relates to methods of using weak partitioning chromatography for the purification of a product from a load fluid containing one or more impurities. Further, the invention relates to methods of weak partitioning chromatography defined by operating conditions which cause a medium to bind least 1 mg of product... Agent: Wilmerhale/wyeth

20070060742 - Antibodies to human tumor necrosis factor receptor: Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070055048 - Process for supported phase synthesis: The present invention relates to an improved process for supported phase synthesis, in particular for supported phase peptide synthesis, that makes use of salts, in particular of quaternary ammonium salts.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070055049 - Hla binding motifs and peptides and their uses: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired... Agent: Sterne, Kessler, Goldstein & Fox Pllc

20070055050 - Methods and reagents for diagnosis and treatment of diabetes: The invention relates to methods and reagents for diagnosing and treating diabetes.... Agent: Townsend And Townsend And Crew, LLP

20070055051 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070055052 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070055053 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070055054 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070055055 - Protein separation from a protein mixture: A process for separating a protein from a sample containing a mixture of proteins is disclosed. The process comprises forming an aqueous combination comprising the sample and an ion exchange material at a pH which is less than the pI of a first fraction of the proteins in the aqueous... Agent: Senniger Powers

20070049727 - Low sulfur tall oil fatty acid: The invention relates to tall oil fatty acid compositions having low sulfur content, as well as methods of using and making the same.... Agent: International Paper Company

20070049728 - Solid phase synthesis supports and methods: Functionalized supports and methods for solid phase synthesis. Preferably, the functionalized support is azlactone-functionalized.... Agent: 3m Innovative Properties Company

20070049729 - Interleukin-17 receptor homologue: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049730 - Patched-2 antibodies: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antibodies, vectors and host cells expressing, immunoadhesins, agonists and antagonists to patched-2.... Agent: Genentech, Inc.

20070049731 - Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue: A method for purifying bone-derived osteoinductive proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recovery process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and... Agent: Williams, Morgan & Amerson

20070049732 - Ultra-high yield intravenous immune globulin preparation: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs sodium citrate in two initial fractionation steps, followed by diafiltration to remove sodium citrate.... Agent: Eugene J. Zurlo

20070049733 - Ultra-high yield intravenous immune globulin preparation: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs sodium citrate in two initial fractionation steps, followed by diafiltration to remove sodium citrate.... Agent: Eugene J. Zurlo

20070049734 - Ultra-high yield intravenous immune globulin preparation: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs one or more salts from a group of salts comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride... Agent: Gene Zurlo

20070049737 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049736 - Interferon-like protein zcyto21: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049735 - Antibodies that bind both bcma and taci: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049738 - Avian leukosis viruses and polypeptide display: The invention provides methods and materials involved in displaying polypeptide sequences using viruses such as avian leukosis viruses. Specifically, the invention provides nucleic acid molecules, collections of nucleic acid molecules, polypeptides, collections of polypeptides, viruses, and collections of viruses as well as methods for making nucleic acid molecules, collections of... Agent: Fish & Richardson P.C.

20070049740 - Mammalian transforming growth factor beta-9: Novel mammalian Ztgfβ-9 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049739 - Method and system for extracting blood-derived growth factors: Methods for extracting heparin-binding growth factors from whole blood comprising contacting whole blood with a heparin-conjugated system to immobilize a conjugated fraction comprising the heparin-binding growth factors; separating a non-conjugated fraction from the system; and releasing the heparin-binding growth factors are provided. Kits include a heparin-conjugate immobilized to the surface... Agent: Harness, Dickey & Pierce, P.L.C

20070049741 - Aminoglycoside-polyamine displacers and methods of use in displacement chromatography: t